0

    524703

    SANDUPHQ

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    SANDU PHARMACEUTICALS LTD. Share Price Today

    Investment Returns

    Over 1 Month -2.35% Over 3 Months 34.37% Over 6 Months 7.83% Over 1 Year -19.19%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    SANDU PHARMACEUTICALS LTD. fundamentals


    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield [-]%
    • Net profit/quarter (Cr) [-]
    info icon alternate text
    • Market cap (Cr) 39.60
    • P/E Ratio (TTM) 22.41
    • Beta 0.66
    • Book Value / share 36.33
    • Return on equity 4.74%
    • EPS (TTM) 1.83
    • Dividend yield [-]%
    • Net profit/quarter (Cr) 0.04
    info icon alternate text

    SANDU PHARMACEUTICALS LTD. Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 16.85
    Operating Expense 16.48
    Net Profit 0.04
    Net Profit Margin (%) 0.23
    Earnings Per Share (EPS) 0.04
    EBITDA 0.94
    Effective Tax Rate (%) 93.33
    Particulars DEC 2025 (Values in Cr)
    Revenue 18.76
    Operating Expense 17.92
    Net Profit 0.98
    Net Profit Margin (%) 5.22
    Earnings Per Share (EPS) 1.01
    EBITDA 1.06
    Effective Tax Rate (%) -13.95
    Particulars SEP 2025 (Values in Cr)
    Revenue 17.62
    Operating Expense 16.96
    Net Profit 0.52
    Net Profit Margin (%) 2.95
    Earnings Per Share (EPS) 0.54
    EBITDA 0.91
    Effective Tax Rate (%) 26.76
    Particulars JUN 2025 (Values in Cr)
    Revenue 16.70
    Operating Expense 16.38
    Net Profit 0.22
    Net Profit Margin (%) 1.31
    Earnings Per Share (EPS) 0.23
    EBITDA 0.55
    Effective Tax Rate (%) 35.29
    Particulars MAR 2025 (Values in Cr)
    Revenue 14.07
    Operating Expense 13.79
    Net Profit 0.33
    Net Profit Margin (%) 2.34
    Earnings Per Share (EPS) 0.34
    EBITDA 0.52
    Effective Tax Rate (%) 5.88
    Particulars MAR 2026 (Values in Cr)
    Revenue 69.93
    Operating Expense 67.72
    Net Profit 1.77
    Net Profit Margin (%) 2.53
    Earnings Per Share (EPS) 1.83
    EBITDA 3.45
    Effective Tax Rate (%) 33.45
    Particulars MAR 2025 (Values in Cr)
    Revenue 67.19
    Operating Expense 65.19
    Net Profit 1.55
    Net Profit Margin (%) 2.30
    Earnings Per Share (EPS) 1.60
    EBITDA 2.93
    Effective Tax Rate (%) 28.24
    Particulars MAR 2024 (Values in Cr)
    Revenue 67.28
    Operating Expense 65.63
    Net Profit 1.46
    Net Profit Margin (%) 2.17
    Earnings Per Share (EPS) 1.51
    EBITDA 2.71
    Effective Tax Rate (%) 29.46
    Particulars MAR 2023 (Values in Cr)
    Revenue 65.35
    Operating Expense 63.46
    Net Profit 1.52
    Net Profit Margin (%) 2.32
    Earnings Per Share (EPS) 1.62
    EBITDA 2.82
    Effective Tax Rate (%) 31.53
    Particulars MAR 2022 (Values in Cr)
    Revenue 65.50
    Operating Expense 63.26
    Net Profit 1.59
    Net Profit Margin (%) 2.42
    Earnings Per Share (EPS) 1.99
    EBITDA 2.96
    Effective Tax Rate (%) 31.46
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 34.63
    ROE % 4.74
    ROCE % 6.87
    Total Debt to Total Equity 0.00
    EBITDA Margin 4.36
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 33.01
    ROE % 4.11
    ROCE % 5.98
    Total Debt to Total Equity 0.00
    EBITDA Margin 4.04
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 40.62
    ROE % 3.87
    ROCE % 5.86
    Total Debt to Total Equity 0.00
    EBITDA Margin 4.30
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 34.63
    ROE % 4.74
    ROCE % 6.87
    Total Debt to Total Equity 0.00
    EBITDA Margin 4.36
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 33.01
    ROE % 4.11
    ROCE % 5.98
    Total Debt to Total Equity 0.00
    EBITDA Margin 4.04
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 40.62
    ROE % 4.56
    ROCE % 6.89
    Total Debt to Total Equity 0.00
    EBITDA Margin 4.32
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 30.71
    ROE % 6.13
    ROCE % 9.37
    Total Debt to Total Equity 0.00
    EBITDA Margin 4.52
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 29.63
    ROE % 4.92
    ROCE % 7.85
    Total Debt to Total Equity 0.03
    EBITDA Margin 4.00
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 2.65
    Total Assets 55.71
    Total Liabilities 55.71
    Total Equity 42.01
    Share Outstanding 0
    Price to Book Ratio 1.41
    Return on Assets (%) 2.78
    Return on Capital (%) 3.69
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 1.20
    Total Assets 52.41
    Total Liabilities 52.41
    Total Equity 40.59
    Share Outstanding 0
    Price to Book Ratio 1.74
    Return on Assets (%) 2.78
    Return on Capital (%) 3.6
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 2.29
    Total Assets 54.16
    Total Liabilities 54.16
    Total Equity 39.24
    Share Outstanding 0
    Price to Book Ratio 1.29
    Return on Assets (%) 2.80
    Return on Capital (%) 3.87
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 2.65
    Total Assets 55.71
    Total Liabilities 55.71
    Total Equity 42.01
    Share Outstanding 0
    Price to Book Ratio 1.41
    Return on Assets (%) 2.77
    Return on Capital (%) 3.69
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 1.19
    Total Assets 52.41
    Total Liabilities 52.41
    Total Equity 40.59
    Share Outstanding 0
    Price to Book Ratio 1.74
    Return on Assets (%) 2.78
    Return on Capital (%) 3.6
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 2.28
    Total Assets 54.16
    Total Liabilities 54.16
    Total Equity 39.24
    Share Outstanding 0
    Price to Book Ratio 1.29
    Return on Assets (%) 2.81
    Return on Capital (%) 3.88
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 4.17
    Total Assets 49.28
    Total Liabilities 49.28
    Total Equity 36.47
    Share Outstanding 0
    Price to Book Ratio 2.29
    Return on Assets (%) 3.22
    Return on Capital (%) 4.36
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 11.65
    Total Assets 46.96
    Total Liabilities 46.96
    Total Equity 33.49
    Share Outstanding 0
    Price to Book Ratio 1.08
    Return on Assets (%) 2.32
    Return on Capital (%) 3.26
    Particulars MAR 2025 (Values in Cr)
    Net Income 2.15
    Cash from Operations 1.53
    Cash from Investing -0.18
    Cash from Financing -0.46
    Net change in Cash 0.30
    Free Cash Flow 2.46
    Particulars MAR 2024 (Values in Cr)
    Net Income 2.07
    Cash from Operations 1.25
    Cash from Investing -1.30
    Cash from Financing -0.72
    Net change in Cash -1.27
    Free Cash Flow 2.68
    Particulars MAR 2023 (Values in Cr)
    Net Income 2.21
    Cash from Operations 0.92
    Cash from Investing 0.53
    Cash from Financing 0.57
    Net change in Cash 1.33
    Free Cash Flow 1.98
    Particulars MAR 2025 (Values in Cr)
    Net Income 2.15
    Cash from Operations 1.53
    Cash from Investing -0.17
    Cash from Financing -0.46
    Net change in Cash 0.30
    Free Cash Flow 2.47
    Particulars MAR 2024 (Values in Cr)
    Net Income 2.07
    Cash from Operations 1.26
    Cash from Investing -1.30
    Cash from Financing -0.72
    Net change in Cash -1.27
    Free Cash Flow 2.68
    Particulars MAR 2023 (Values in Cr)
    Net Income 2.22
    Cash from Operations 0.92
    Cash from Investing 0.52
    Cash from Financing 0.57
    Net change in Cash 1.32
    Free Cash Flow 1.98
    Particulars MAR 2022 (Values in Cr)
    Net Income 2.31
    Cash from Operations 1.82
    Cash from Investing -5.47
    Cash from Financing 0.93
    Net change in Cash -3.58
    Free Cash Flow 2.66
    Particulars MAR 2021 (Values in Cr)
    Net Income 1.68
    Cash from Operations 8.04
    Cash from Investing -5.57
    Cash from Financing 1.29
    Net change in Cash 3.31
    Free Cash Flow 8.17
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.08 12.84 1.50 238.18 23.12 38.85
    BLISS GVS PHARMA LTD 530.35 43.05 4.71 5624.69 118.35 541.75
    CIPLA LTD 1453.50 30.85 3.41 117420.32 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 356.70 15.73 2.58 1049.80 256.40 399.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.08 21.73 4.00 238.18 23.12 38.85
    AMRUTAJAN HEALTH LTD 539.05 24.16 4.20 1558.43 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8054.15 105.19 23.07 20135.38 7630.00 9850.00
    BLISS GVS PHARMA LTD 530.35 57.21 4.86 5624.69 118.35 541.75

    SANDU PHARMACEUTICALS LTD. shareholding pattern

    Holding
    62.2%
    37.78%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    SANDU PHARMACEUTICALS LTD. Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    41.00 -0.02 redarrow
    red-green-graph indicator
    12 Bearish
    4 Bullish
    • 5 Days 41.50
    • 26 Days 41.70
    • 10 Days 41.80
    • 50 Days 40.80
    • 12 Days 41.80
    • 100 Days 40.00
    • 20 Days 41.80
    • 200 Days 41.30
    41.07 PIVOT
    First Support 40.54 First Resistance 41.54 Second Support 40.07 Second Resistance 42.07 Third Support 39.54 Third Resistance 42.54
    RSI 46.96 ADX 68.89 MACD 0.15 Williams % R -81.64 Commodity Channel Index (CCI) -142.70
    Date 2026-06-29 Week 2960.00 Same Day 125.00 Month 2367.00
    1 Year 0.67 3 Year 0.66
    Over 1 Month
    -2.35% down
    Over 1 Year
    -19.19% down
    Over 3 Months
    34.37% down
    Over 3 Years
    -9.71% down
    Over 6 Months
    7.83% down
    Over 5 Years
    -6.74% down

    SANDU PHARMACEUTICALS LTD. Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    18 Sep 2025 0.8 Final 18 Sep 2025 Equity shares
    19 Sep 2024 0.8 Final 20 Sep 2024 Equity shares
    18 Sep 2023 0.75 Final 19 Sep 2023 Equity shares
    23 Sep 2022 0.75 Final 23 Sep 2022 Equity shares
    22 Sep 2021 0.5 Final 24 Sep 2021 Equity shares

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Sandu Pharmaceuticals Ltd?

    Answer Field

    Sandu Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 41.00 as on Jul 01 2026 03:30 PM.

    What is the Market Cap of Sandu Pharmaceuticals Ltd Share?

    Answer Field

    The market cap of Sandu Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 39.60 as on Jul 01 2026 03:30 PM.

    What is the 52 Week High and Low of Sandu Pharmaceuticals Ltd?

    Answer Field

    The 52 Week High and Low of Sandu Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 58.28 and ₹ 30.00.

    What is 1 year return for Sandu Pharmaceuticals Ltd?

    Answer Field

    The 1 year returns on the stock has been -19.19%.

    What is the P/E Ratio of Sandu Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 01 2026 03:30 PM the price-to-earnings (PE) ratio for Sandu Pharmaceuticals Ltd share is 22.41.

    What is the PB ratio of Sandu Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 01 2026 03:30 PM, the price-to-book (PB) ratio for Sandu Pharmaceuticals Ltd share is 36.33.

    How to Buy Sandu Pharmaceuticals Ltd Share?

    Answer Field

    You can trade in Sandu Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Sandu Pharmaceuticals Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Sandu Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Sandu Pharmaceuticals Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |